|
BioScreening - organic compounds for screening
Targeted Libraries News7TH DUESSELDORF SYMPOSIUM ON IMMUNOTOXICOLOGY Biology of the Arylhydrocarbon Receptor - Heinrich Heine University Duesseldorf September 21 – 24, 2011 AhR research has taken great momentum recently, with a number of seminal discoveries, especially regarding its role in physiological events. This has opened new arenas, attracted new groups into the field, and led to a steep interest in the potential of AhR as a therapeutic target [...]
BioFocus to Offer IMD’s Natural Product Libraries through Drug Discovery Services - BioFocus and InterMed Discovery (IMD) inked a marketing collaboration that will allow BioFocus to offer IMD’s natural product screening libraries through its drug discovery services. IMD will in addition provide follow-on services to BioFocus. “We have been impressed with the scale of IMD’s natural product discovery capabilities, and we believe that when InterMed’s natural product [...]
Molecular Target for Screening: G-Protein-Coupled Receptors - Newark, DE. August, 2010 – Press Release – TimTec, LLC. – Molecular Target for Screening: G-Protein-Coupled Receptors, ActiTarg-G G-Protein-Coupled Receptors are the largest gene families in the human genome and, rightfully so, have become the leading molecular target in 2008. In 2009 SBS April meeting in Lille, France, followed-up with screening trends report stating that [...]
TimTec Expands Partnership With Collaborative Drug Discovery Through Publishing Three Additional Libraries on CDD’s Free Public Access Database - Last October, TimTec and Collaborative Drug Discovery (CDD) established a collaboration in which CDD’s web-based data management system would host two TimTec Natural Products libraries on their free community Public Access site.  Through this partnership, researchers would be able to register for a free account with CDD allowing them to chemically mine the contents of these TimTec [...]
KINAXO’s Cellular Target Profiling® reveals mTOR as a new target of Celebrex - Martinsried, Germany, April 29, 2009 / b3c newswire / - Kinaxo Biotechnologies GmbH has successfully applied its Cellular Target Profiling® technology to identify the protein kinase mTOR as a new cellular target of celecoxib (Celebrex®, Pfizer). Celecoxib is a non-steroidal, anti-inflammatory Cox-2 inhibitor approved for the treatment of osteoarthritis, rheumatoid arthritis and acute pain. In addition, [...]
Plexxikon Receives Key Patents on Novel Compounds for Multiple Programs - BERKELEY, Calif.–(BUSINESS WIRE)–Plexxikon Inc. today announced the issuance of key composition-of-matter patents covering novel compounds discovered through the company’s Scaffold-Based Drug Discoveryâ„¢ platform. Plexxikon’s pipeline of preclinical and clinical stage product opportunities currently span potential treatments for cardio-renal disease, CNS disorders, inflammation, metabolic disease and oncology. Two of the three recently issued patents (U.S. patents [...]
Plexxikon Receives Key Patents on Novel Compounds for Multiple Programs - BERKELEY, Calif.–(BUSINESS WIRE)–Plexxikon Inc. today announced the issuance of key composition-of-matter patents covering novel compounds discovered through the company’s Scaffold-Based Drug Discoveryâ„¢ platform. Plexxikon’s pipeline of preclinical and clinical stage product opportunities currently span potential treatments for cardio-renal disease, CNS disorders, inflammation, metabolic disease and oncology. Two of the three recently issued patents (U.S. patents [...]
Ligand Pharmaceuticals Inc. (LGND) Enters into Screening Agreement with Trevena - SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – News) and Trevena Inc. today announced the initiation of a joint research and license alliance to screen targets using Trevena’s novel biological platform against Ligand’s combinatorial library of compounds, to identify active compounds with potential for development as novel G-protein coupled receptor (GPCR) therapeutics. Under the terms of [...]
Galapagos enters strategic alliance in diabetes and obesity with Merck & Co., Inc. - Galapagos NV (Euronext: GLPG) announced today that it has entered into a multi-year global strategic alliance with Merck & Co., Inc. to develop potential new therapies in obesity and diabetes. Galapagos will be responsible for the discovery and pre-clinical development of new small molecule candidate drugs based on novel Galapagos targets. Merck will have the [...]
Trends in Drug Research 27th Noordwijkerhout-Camerino-Cyprus Conference Noordwijkerhout, The Netherlands, May 3 – 8, 2009 - The Symposium is sponsored by the European Federation of Medicinal Chemistry (EFMC). The Organising and Scientific Committees cordially invite you to attend the 27 edition of this meeting on Trends in Drug Research. The interplay between molecular structure and biological activity is central to contemporary biomedical and translational research, relevant not only to structural biologists [...]
Fragment Based Screening Service at CRELUX and ZoBio - Munich (D) and Leiden (NL), November 24, 2008 / b3c newswire / – CRELUX and ZoBio announced today that they have successfully executed their first fragment based screening projects from a jointly established platform. One of the first targets, which also will be made accessible to customers, was Pim1, a kinase that has been implicated [...]
Virtual Screening Gives Drug Design a Boost - San Diego, CA (OBBeC) – Researchers at the University of California, San Diego, developed a unique computational approach to identify key compounds that could lead to new drugs to combat African sleeping sickness — a disease spread by the biting tsetse fly and caused by the parasite Trypanosoma brucei. Around 150,000 people per year get [...]
TOCRIS SIGNS EXCLUSIVE DEAL TO SUPPLY GEFITINIB - September 4th, 2008 – Tocris Bioscience announced today the signing of an exclusive deal with AstraZeneca to supply Gefitinib (also known as Iressa and ZD1839) to preclinical researchers working on the mechanisms underlying cancer development. For the first time, scientists will be able to buy authentic, fully licensed, non-formulated Gefitinib as an off-the shelf product [...]
Ion Channel Targets 2008 9 – 10 September 2008, South San Francisco, CA, USA - Select Biosciences is proud to announce their 4th annual Ion Channel Targets conference and exhibition. This year’s event will take place at the South San Francisco Conference Center. Alongside an exhibition of selected scientific posters and service providers, Select Biosciences is organizing a two day event gathering some of the most influential players in the [...]
CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform - Munich and Freiburg, Germany, May 7, 2008 / b3c newswire / – CRELUX and ProQinase announced today that they have entered into a joint agreement to supply customers with crystal-grade protein kinases and readily available kinase complex structures. Under the agreement, CRELUX and ProQinase will establish and continuously expand an off-the-shelf crystal-grade protein kinase portfolio, [...]
Graffinity Announces Multitarget Drug Discovery Research Collaboration With Pfizer - Heidelberg, Germany, November 29, 2007 /b3c newswire/ — Graffinity Pharmaceuticals GmbH announced today that it has entered into its second drug discovery collaboration with Pfizer, Inc. Through the collaboration, Graffinity will provide Pfizer with access to its proprietary, fragment-based screening technology for use in screening Pfizer drug targets. The agreement is Graffinity’s sixth discovery collaboration [...]
7th Annual Protein Kinases Congress 10-12 March 2008 in Crowne Plaza Berlin City Centre, Berlin, Germany - Innovating kinase inhibitor development is the key to successful clinical development. At Informa Life Sciences 7th Annual Protein Kinases Congress hear the latest thinking and strategies towards creating a selective inhibitor. Learn about new targets, industry trends in structure-based drug design, clinical case-studies and discuss the issue of cardiotoxicity. For more information visit: http://www.iir-events.com/IIR-Conf/page.aspx?id=9547
NEW KINASE ProHit COMPOUND SETS - OTAVA, the company that specializes in combinatorial chemistry, fluorescent probes and drug discovery technologies, offers unique ProHit compounds displaying inhibitory activity against distinct protein kinases. ProHit Compound Sets are distributed on an exclusive basis and can be used in the development of drugs targeting protein kinase enzymes. Every Kinase ProHit Compound Set is organized as [...]
Bucks County’s Institute for Hepatitis and Virus Research and BioLeap Collaborate on New Discoveries - New Hope, PA — (SBWIRE) — 10/10/2007 — Bucks County’s Institute for Hepatitis and Virus Research (IHVR) and BioLeap have entered into a collaboration to develop new therapeutic compounds for the treatment of Hepatitis C. Up to 50% of patients treated with current standard therapies do not respond adequately and often suffer serious side effects [...]
Dr. Stephen Burley, SGX Pharmaceuticals–Keynote speaker at 3rd Modern Drug Discovery & Development - (PRLog.Org) – Oct 17, 2007 – MONROVIA, CA – Dr. Stephen K. Burley, Chief Scientific Officer and Senior Vice-President Research at SGX Pharmaceuticals, Inc. located in San Diego, CA will give the Keynote presentation at GTCbio’s Drug Design & Lead Discovery conference – one of six tracks at the 3rd Modern Drug Discovery & Development [...]
Sponsored Links
|
|
